Glenn Alan Carr, MD
Internal Medicine · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 10 years
- Graduated 2016
Offices
1 location · Saint Agnes Medical Foundation · 161 clinicians in this group
Looking this up.
Hospitals listed: Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Carr’s office at (559) 450-5777 to ask if they take your plan before you enroll.
California Medical Board record
Licence A164932 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 31.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$20,704
Medicare paid this office $20,704 for 84 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $10,409 | $139 |
| Advance care planning, first 30 minutes | 68 | $4,493 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,274 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 37 | $2,131 | $39 |
Procedures year by year
| Procedure | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Removal of impacted ear wax | – | 13 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
84 Original Medicare patients in 2024. Average age 79 · 85 and older 39% · Women 57% · Also on Medicaid 54% · Health risk score 2.50. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 69% · Chronic kidney disease 60% · Heart failure 57% · Coronary heart disease 45% · Atrial fibrillation 44% · COPD 40% · Depression 39% · Dementia 38% · Stroke 27% · Cancer 26%.
The office billed $71,546, Medicare allowed $25,872 and paid $20,704; for 253 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 84 | 253 | 79 | 2.50 | $71,546 | $20,704 |
| 2023 | 68 | 148 | 67 | 1.64 | $26,335 | $10,346 |
| 2022 | 162 | 247 | 77 | 1.07 | $69,490 | $20,461 |
| 2021 | 328 | 917 | 77 | 1.12 | $290,191 | $77,798 |
| 2020 | 205 | 503 | 76 | 1.07 | $103,800 | $36,394 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 49 | $6,761 | $101 |
| Short return visit (20+ min) | 15 | $970 | $65 |
2022: 2 services
| Return visit (30+ min) | 147 | $16,956 | $89 |
| Short return visit (20+ min) | 15 | $1,115 | $74 |
2021: 13 services
| Return visit (30+ min) | 268 | $46,695 | $93 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 73 | $10,049 | $138 |
| Short return visit (20+ min) | 67 | $4,880 | $66 |
| Transitional care management services for problem of high complexity | 14 | $3,959 | $247 |
| New patient visit (45+ min) | 39 | $3,532 | $91 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 17 | $2,964 | $174 |
| Influenza vaccine split virus, preservative free | 19 | $1,240 | $65 |
| Annual depression screening, 5 to 15 minutes | 53 | $1,043 | $20 |
| Dxa bone density measurement of hip, pelvis, spine | 22 | $895 | $41 |
| Removal of impacted ear wax | 11 | $474 | $36 |
| Administration of influenza virus vaccine | 20 | $356 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $136 | $10 |
| Automated urinalysis test | 24 | $59 | $2 |
2020: 8 services
| Return visit (30+ min) | 158 | $16,791 | $87 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 45 | $5,464 | $121 |
| Short return visit (20+ min) | 46 | $2,860 | $58 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 14 | $2,501 | $179 |
| Influenza vaccine split virus, preservative free | 34 | $2,073 | $61 |
| New patient visit (45+ min) | 15 | $1,865 | $124 |
| Annual depression screening, 5 to 15 minutes | 52 | $999 | $19 |
| Administration of influenza virus vaccine | 36 | $636 | $18 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their 362 Part D prescriptions in 2023.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 362 | 97 | 3% (12) | None | $25,175 |
| 2022 | 1,682 | 307 | 2% (38) | None | $148,543 |
| 2021 | 2,394 | 374 | 3% (67) | None | $205,939 |
| 2020 | 459 | 154 | 5% (23) | None | $21,584 |
| 2017 | 83 | 48 | None | 18% | $4,402 |
| 2015 | 12 | None | 0% (0) | 0% | $492 |
| 2014 | 81 | 33 | 0% (0) | None | $17,985 |
| 2013 | 2,141 | 360 | 1% (21) | 32% | $211,185 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Trelegy Ellipta | 15 | $10,362 | $691 |
| Atorvastatin | 24 | $581 | $24 |
| Trospium Chloride | 11 | $466 | $42 |
| Mirtazapine | 17 | $243 | $14 |
| Gabapentin | 11 | $214 | $19 |
| Lisinopril | 16 | $170 | $11 |
| Metoprolol | 11 | $108 | $10 |
2022: 34 drugs
| Eliquis | 23 | $23,128 | $1,006 |
| Repatha Sureclick | 19 | $9,829 | $517 |
| Lantus Solostar | 14 | $6,065 | $433 |
| Atorvastatin | 133 | $1,637 | $12 |
| Levothyroxine | 88 | $1,635 | $19 |
| Rosuvastatin | 66 | $1,581 | $24 |
| Albuterol Sulfate Hfa | 29 | $1,357 | $47 |
| Ezetimibe | 14 | $1,033 | $74 |
| Metoprolol | 42 | $967 | $23 |
| Tamsulosin | 54 | $763 | $14 |
| Losartan | 54 | $696 | $13 |
| Gabapentin | 43 | $597 | $14 |
| Hydrocodone-Acetaminophen | 25 | $563 | $23 |
| Potassium Chloride | 15 | $528 | $35 |
| Amlodipine Besylate | 77 | $527 | $7 |
| Metformin | 51 | $416 | $8 |
| Temazepam | 14 | $415 | $30 |
| Pantoprazole | 22 | $369 | $17 |
| Lisinopril | 59 | $359 | $6 |
| Trazodone | 22 | $346 | $16 |
| Metoprolol | 28 | $244 | $9 |
| Allopurinol | 23 | $205 | $9 |
| Fluticasone Propionate | 16 | $203 | $13 |
| Omeprazole | 25 | $177 | $7 |
| Lisinopril-Hydrochlorothiazide | 19 | $176 | $9 |
| Hydrochlorothiazide | 29 | $168 | $6 |
| Triamcinolone Acetonide | 17 | $140 | $8 |
| Simvastatin | 17 | $132 | $8 |
| Sertraline | 16 | $131 | $8 |
| Cyclobenzaprine | 12 | $122 | $10 |
| Citalopram Hbr | 16 | $107 | $7 |
| Diazepam | 12 | $101 | $8 |
| Clonazepam | 12 | $90 | $8 |
| Azithromycin | 15 | $76 | $5 |
2021: 57 drugs
| Eliquis | 43 | $28,196 | $656 |
| Farxiga | 12 | $9,811 | $818 |
| Repatha Sureclick | 19 | $9,486 | $499 |
| Lantus Solostar | 12 | $5,200 | $433 |
| Brilinta | 11 | $4,419 | $402 |
| Albuterol Sulfate Hfa | 70 | $2,955 | $42 |
| Levothyroxine | 121 | $2,891 | $24 |
| Atorvastatin | 169 | $2,036 | $12 |
| Rosuvastatin | 63 | $1,932 | $31 |
| Gabapentin | 54 | $1,604 | $30 |
| Metoprolol | 45 | $1,312 | $29 |
| Losartan | 83 | $1,236 | $15 |
| Pantoprazole | 44 | $1,080 | $25 |
| Synthroid | 12 | $996 | $83 |
| Temazepam | 14 | $995 | $71 |
| Valsartan-Hydrochlorothiazide | 14 | $972 | $69 |
| Tamsulosin | 49 | $915 | $19 |
| Amlodipine Besylate | 100 | $776 | $8 |
| Febuxostat | 11 | $626 | $57 |
| Ranolazine Er | 12 | $604 | $50 |
| Trazodone | 33 | $536 | $16 |
| Lisinopril | 73 | $487 | $7 |
| Omeprazole | 41 | $461 | $11 |
| Hydrocodone-Acetaminophen | 40 | $453 | $11 |
| Montelukast | 16 | $431 | $27 |
| Metformin | 71 | $422 | $6 |
| Fenofibrate | 12 | $387 | $32 |
| Ezetimibe | 18 | $355 | $20 |
| Nitrofurantoin Mono-Macro | 24 | $296 | $12 |
| Valacyclovir | 16 | $292 | $18 |
| Sertraline | 17 | $255 | $15 |
| Lisinopril-Hydrochlorothiazide | 27 | $249 | $9 |
| Amlodipine Besylate-Benazepril | 11 | $232 | $21 |
| Allopurinol | 14 | $224 | $16 |
| Citalopram Hbr | 26 | $216 | $8 |
| Metoprolol | 26 | $203 | $8 |
| Quetiapine | 18 | $202 | $11 |
| Alprazolam | 22 | $193 | $9 |
| Fluticasone Propionate | 14 | $179 | $13 |
| Clopidogrel | 15 | $177 | $12 |
| Diazepam | 35 | $173 | $5 |
| Hydrochlorothiazide | 33 | $169 | $5 |
| Doxycycline Monohydrate | 15 | $157 | $10 |
| Escitalopram | 11 | $155 | $14 |
| Amoxicillin-Clavulanate Potass | 11 | $145 | $13 |
| Simvastatin | 16 | $136 | $9 |
| Carvedilol | 11 | $128 | $12 |
| Triamcinolone Acetonide | 15 | $122 | $8 |
| Furosemide | 18 | $95 | $5 |
| Zolpidem | 17 | $78 | $5 |
| Cyclobenzaprine | 26 | $78 | $3 |
| Atenolol | 14 | $74 | $5 |
| Ciprofloxacin | 19 | $72 | $4 |
| Meloxicam | 14 | $72 | $5 |
| Clonazepam | 11 | $60 | $5 |
| Lorazepam | 15 | $51 | $3 |
| Tramadol | 14 | $39 | $3 |
2020: 10 drugs
| Atorvastatin | 27 | $360 | $13 |
| Tamsulosin | 13 | $322 | $25 |
| Levothyroxine | 13 | $291 | $22 |
| Gabapentin | 12 | $210 | $18 |
| Alprazolam | 15 | $162 | $11 |
| Nitrofurantoin Mono-Macro | 14 | $156 | $11 |
| Lisinopril | 20 | $140 | $7 |
| Hydrocodone-Acetaminophen | 13 | $140 | $11 |
| Amlodipine Besylate | 21 | $119 | $6 |
| Metformin | 11 | $100 | $9 |
2017: 1 drug
| Azithromycin | 12 | $57 | $5 |
2013: 53 drugs
| Crestor | 83 | $22,420 | $270 |
| Advair Diskus | 31 | $14,824 | $478 |
| Nexium | 26 | $11,673 | $449 |
| Lovaza | 33 | $8,479 | $257 |
| Niaspan | 28 | $7,769 | $277 |
| Zetia | 29 | $7,428 | $256 |
| Welchol | 14 | $6,462 | $462 |
| Janumet | 12 | $5,501 | $458 |
| Januvia | 14 | $5,018 | $358 |
| Metoprolol | 93 | $4,256 | $46 |
| Namenda | 15 | $3,966 | $264 |
| Lantus | 20 | $3,843 | $192 |
| Atorvastatin | 66 | $2,872 | $44 |
| Detrol La | 14 | $2,761 | $197 |
| Vytorin | 11 | $1,820 | $165 |
| Clopidogrel | 42 | $1,651 | $39 |
| Propafenone | 16 | $1,585 | $99 |
| Potassium Chloride | 17 | $1,399 | $82 |
| Oxybutynin Chloride Er | 15 | $1,335 | $89 |
| Simvastatin | 96 | $1,323 | $14 |
| Escitalopram | 12 | $1,250 | $104 |
| Levothyroxine | 98 | $1,224 | $12 |
| Omeprazole | 53 | $1,211 | $23 |
| Carvedilol | 64 | $1,063 | $17 |
| Amlodipine Besylate | 73 | $1,037 | $14 |
| Lisinopril | 77 | $946 | $12 |
| Warfarin | 64 | $899 | $14 |
| Tamsulosin | 35 | $860 | $25 |
| Fluticasone Propionate | 23 | $851 | $37 |
| Hydrochlorothiazide | 52 | $590 | $11 |
| Losartan | 14 | $570 | $41 |
| Bupropion Xl | 12 | $556 | $46 |
| Metformin | 41 | $543 | $13 |
| Gabapentin | 19 | $532 | $28 |
| Sulfasalazine | 20 | $512 | $26 |
| Polyethylene Glycol 3350 | 16 | $461 | $29 |
| Ramipril | 13 | $392 | $30 |
| Pravastatin | 16 | $343 | $21 |
| Triamterene-Hydrochlorothiazid | 26 | $331 | $13 |
| Benazepril-Hydrochlorothiazide | 13 | $323 | $25 |
| Metformin Hcl Er | 22 | $300 | $14 |
| Atenolol | 34 | $283 | $8 |
| Citalopram Hbr | 23 | $280 | $12 |
| Synthroid | 12 | $263 | $22 |
| Alendronate | 12 | $221 | $18 |
| Metolazone | 12 | $217 | $18 |
| Digox | 17 | $176 | $10 |
| Lisinopril-Hydrochlorothiazide | 13 | $172 | $13 |
| Sulindac | 15 | $160 | $11 |
| Clonazepam | 18 | $157 | $9 |
| Allopurinol | 11 | $135 | $12 |
| Furosemide | 17 | $104 | $6 |
| Zolpidem | 12 | $69 | $6 |
Money from drug and device companies
$18 in 2025
| 2025 | 1 | 1 | None | $18 |
| 2023 | 4 | 11 | None | $260 |
| 2022 | 21 | 54 | None | $1,102 |
| 2021 | 26 | 184 | None | $2,956 |
| 2020 | 18 | 36 | None | $733 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Synchromedii | $18 | 1 payment
|
See the published payment
| Medtronic | Meals · 2025-02-19 | Synchromedii | $18 |
See earlier years (2023, 2022, 2021, 2020)
2023: $260
| AstraZeneca Pharmaceuticals LP | Farxiga | $189 | 5 payments
|
| AbbVie | Qulipta | $32 | 1 payment
|
| VBI Vaccine (Delaware) | Prehevbrio | $21 | 1 payment
|
| Lilly USA | Mounjaro | $19 | 1 payment
|
2022: $1,102
| AstraZeneca Pharmaceuticals LP | Farxiga | $208 | 5 payments
|
| Abbvie | Qulipta | $133 | 8 payments
|
| SK Life Science | None | $97 | 3 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $94 | 5 payments
|
| Lilly USA | Mounjaro | $59 | 4 payments
|
| Esperion Therapeutics | Nexletol | $56 | 3 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $51 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $51 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $50 | 3 payments
|
| Daiichi Sankyo | Injectafer | $46 | 2 payments
|
| Novo Nordisk | Rybelsus | $44 | 2 payments
|
| Amgen | Evenity | $39 | 2 payments
|
| Kowa Pharmaceuticals America | Livalo | $31 | 1 payment
|
| Almatica Pharma | Gralise | $25 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $21 | 1 payment
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $19 | 1 payment
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $18 | 1 payment
|
| Nevro | Omnia | $16 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $16 | 1 payment
|
| VBI Vaccines (Delaware) | Prehevbrio | $15 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $12 | 1 payment
|
2021: $2,956
| Amgen | Repatha | $438 | 16 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $422 | 5 payments
|
| AbbVie | Ubrelvy | $368 | 28 payments
|
| Novo Nordisk | Rybelsus | $289 | 12 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $220 | 12 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $139 | 13 payments
|
| Pfizer | Premarin | $138 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Tradjenta | $123 | 11 payments
|
| Otsuka America Pharmaceutical | Rexulti | $110 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $95 | 6 payments
|
| Lilly USA | Trulicity | $87 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $83 | 3 payments
|
| Daiichi Sankyo | Injectafer | $75 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $70 | 5 payments
|
| Abbott Laboratories | Freestyle Libre 2 | $46 | 2 payments
|
| Merck Sharp & Dohme | Januvia | $40 | 3 payments
|
| Boston Scientific | Superion | $39 | 2 payments
|
| Esperion Therapeutics | Nexletol | $32 | 2 payments
|
| Radius Health | Tymlos | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $23 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $19 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $18 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $14 | 1 payment
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $13 | 1 payment
|
| Philips Electronics North America | (8874) Incourage | $12 | 1 payment
|
2020: $733
| Pfizer | Eliquis | $125 | 1 payment
|
| Novo Nordisk | Ozempic | $85 | 5 payments
|
| Allergan | Ubrelvy | $84 | 4 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $49 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $46 | 3 payments
|
| Eisai | Dayvigo | $37 | 2 payments
|
| Boston Scientific | Superion | $35 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $35 | 2 payments
|
| Lilly USA | Emgality | $35 | 2 payments
|
| Daiichi Sankyo | Injectafer | $34 | 2 payments
|
| Amgen | Repatha | $34 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $25 | 2 payments
|
| AbbVie | Mavyret | $24 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $19 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $18 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $17 | 1 payment
|
| Esperion Therapeutics | Nexletol | $17 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $14 | 1 payment
|
Professional record
- NPI
- 1740566736
- Licence
- CA A164932California A164932: Current · expires 2027-08-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0002X (207RH0002X); Internal medicine (207R00000X)
- Mailing address
- 7145 N Chestnut Ave Ste 101, Fresno, CA, 93720
- NPI first listed
- 2011-10-23
- NPI last updated
- 2025-01-07
- NPI record certified
- 2025-01-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 7145 N Chestnut Ave Ste 101, Fresno, CA, 93720